ACTRN12614000133639尚未招募2 期
In metastatic colorectal cancer patients with systemic inflammation, is daily simvastatin feasible and safe to add to standard chemotherapy?
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients must fulfill ALL of the following criteria to be eligible for admission to the study:
- •* Radiological or pathologically confirmed metastatic colorectal cancer
- •* Measurable or evaluable disease
- •* Eligible for XELOX, mFOLFOX6, or FOLFIRI plus bevacizumab in accordance with local standards of care and pharmaceutical benefits scheme approvals
- •* Evidence of systemic inflammation - NLR > or = 5
- •* WHO performance status of 0, 1 or 2
- •* Adequately recovered from recent surgery. At least 4 weeks must have elapsed from major surgery.
- •* Life expectancy of > 3 months
- •* Hematology performed within 28 days of starting study treatment and with values within the ranges specified below
- •- Absolute granulocytes/neutrophils > 1.5 x 109 /L
- •- Platelets > 100 x 109/L
- •- Hemoglobin > 80g/L
- •* Biochemistry performed within 28 days of starting study treatment and with values within the ranges specified below
- •- Total bilirubin < 1.5 x institutional upper limit of normal (< 2.0 x with documented liver metastases)
- •- ALT < 2.5 x institutional upper limit of normal (< 5.0 x with documented liver metastases)
- •- AST < 2.5 x institutional upper limit of normal (< 5.0 x with documented liver metastases)
- •- Serum creatinine < 1.5 x institutional upper limit of normal or Creatinine Clearance > 50ml/min
- •- Magnesium > 0.5mM (1.2 mg/dL)
- •- Creatine phosphokinase < 2.5 x institutional upper limit of normal
- •* Patient must consent to provision of access to a representative formalin fixed paraffin block of tumour tissue for future research studies to be conducted. Where no previously resected or biopsied tumour tissue exists the patient may still be eligible for the study.
- •* Patient must consent to provision of blood samples.
- •* Age over 18 years
- •* Patient consent for trial participation must be obtained according to local Institutional Human Research Ethics Committee (HREC) requirements.
- •* Patients must be accessible for treatment and follow-up.
- •* The patient is not receiving therapy in a concurrent clinical study that involves systemic therapy or radiotherapy. The patient may enroll in biomarker studies and psychosocial studies.
- •* Patient agrees not to seek statin therapy during and/or after the completion of the study.
排除标准
- •Patients who fulfill any of the following criteria are not eligible for admission to the study:
- •* Prior chemotherapy for metastatic colorectal cancer or adjuvant chemotherapy completed in the last 6 months
- •* Radiotherapy within 28 days prior to enrolment or not recovered from a radiotherapy course
- •* A history of other malignancies with the exception of: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence for > 3 years.
- •* Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation). History of a significant bleeding event or felt by the investigator to be at risk of such events.
- •* Significant vascular disease (e.g. aortic aneurysm requiring surgical intervention).
- •* Peripheral arterial thrombosis or other arterial thrombotic events within 6 months
- •prior to commencement of study treatment.
- •* Inadequately controlled hypertension (defined as values consistently 150/100 mmHg despite use of at least three standard antihypertensive medications).
- •* Prior history of hypertensive crisis or hypertensive encephalopathy.
- •* Clinically significant (i.e. active) cardiovascular disease (e.g. NYHA Class II or greater congestive heart failure).
- •* Pregnant or lactating females (a serum pregnancy test to be assessed within 7 days prior to study treatment, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment).
- •* Women of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) not using appropriate method of contraception and not willing to use an effective method of contraception during the study and for 6 months after the last dose of study medication. Oral or injectable contraceptive agents cannot be the sole method of contraception.
- •* Male patients must be surgically sterile or agree to use a barrier method of contraception.
- •* Any condition (e.g. psychological, geographical etc) that does not permit compliance with the protocol.
- •* Presence of active inflammatory bowel disease, infection or rheumatological condition.
- •* Previous history or current evidence of rhabdomyolsis or myopathy.
- •* Receipt of the investigational drug, simvastatin, or member of the statin class of drugs within the last 28 days
- •* Receipt of regular dosing of NSAIDs for a period of 2 weeks or more (excluding 8mg dexamethasone used for preventing hypersensitivity reactions) or corticosteroids (dose > 10 mg/day methylprednisolone equivalent).
- •* History of allergy to simvastatin or other statin drugs.
- •* Currently taking contraindicated medications of simvastatin (CYP3A4 or OATP1B1 inhibitors). Simvastatin is a CYP3A4 and OATP1B1 substrate that has demonstrated clinically relevant drug interactions with other known CYP3A4 and OATP1B1 substrates, inhibitors and inducers. Warfarin is a weak substrate for CYP3A4 and use of warfarin as anticoagulant should be undertaken only with caution and close monitoring of INR and consideration should be given to switching the patient to low molecular weight heparin for the duration of the study.
- •* Patients who are not able to swallow tablets.
研究者
相似试验
终止
不适用
In colorectal metastases patients who require liver resection, does a surgeon having knowledge of liver fat measurements influence surgical planning decisions that result in improved patient outcomes.ACTRN12615000567527Resonance Health Ltd20
尚未招募
不适用
Outcomes of colorectal cancer patients undergoing elective and emergency surgeriesCTRI/2021/11/038084JIPMER
已完成
不适用
Cohort study of Patients with metastatic colorectal cancer Treated by XELOX with bevacizumabcolorectal cancerJPRN-UMIN000004896agoya City University Gastrointestinal Surgery38
尚未招募
不适用
Refractory advanced colorectal cancer in the treatment with integrated traditional Chinese and western medicine: a multi-center clinical studycolorectal cancerITMCTR2200006741onghua Hospital, Shanghai University of Traditional Chinese Medicine
已完成
不适用
Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal CancerRectal CancerColorectal CancerColon CancerNCT00807313Universitair Ziekenhuis Brussel53